- 24 women making moves in healthcare
- Investors renew fight against UnitedHealth, claiming $237M in insider stock sales
- Texas Health Resources CEO on forgoing M&A: ‘All those cases so far would be dilutive’
- What drives a US News Honor Roll hospital: 4 operational themes from 6 execs
- Luigi Mangione admits he shot UnitedHealthcare CEO
- Cleveland Clinic posts 5% operating margin in Q2: 5 things to know
- The ‘hidden tax’ squeezing hospital supply chains
- DermCare Management, US Dermatology Partners form national dermatology group
- HCA plans $300M Florida hospital
- 346 healthcare organizations named Forbes’ best-in-state employers
- The real reason ASC anesthesia departments struggle — and it’s not operations
- Single payer system would save $1 trillion, 114,000 lives annually: Yale study
- Nevada cuts psychiatric residential placements for children from 35% to 16%
- Seattle Children’s expands with $103M ASC
- 5 cardiologists in the headlines
- The toughest talks ASC leaders have with physicians
- Alabama developers to break ground on $35M ASC
- The specialties driving ASC growth through 2031
- Is the behavioral health access problem actually a quality problem?
- Nurses at SSM Health outpatient practices move to unionize
- 62% of ASCs cancel, delay cases over anesthesia gaps
- Processed Foods Linked To Prostate Cancer Risk
- Screen Time Is Not All Bad For Kids' Brains
- Winter Is Coming: How Vaccines Help Protect Against Respiratory Illness
- Updated Statement Regarding the Division of Corporation Finance’s Role in the Exchange Act Rule 14a-8 Process
- Luigi Mangione pleads guilty in federal case over murder of UnitedHealthcare CEO Brian Thompson
- It's BMS vs. Celgene investors once more after US appeals court revives lawsuit
- Tavneos trial flagged for 'serious breaches' of protocol as EU regulators dissect market withdrawal decision
- Sleep Disturbances Linked To Genetic Alzheimer's Risk
- Pre-K Sets Kids Up For School Success, Study Says
- Expect Other Seniors To Act Their Age? Then Expect Problems With Your Own Memory, Study Says
- People With Disabilities Say Medicaid Income Limits Stifle Career Advancement
- A genomics library for the AI era
- BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod
- My Husband Was Kicked Out of Hospice for Dying Too Slowly
- Trump Team’s Use of Arcane Budget Rule Threatens Medicaid Coverage
- Massachusetts moves to restrict kratom sales
- Meet the leaders of the fastest-growing dental practices
- Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
- Will cardiology’s ASC strategy pay off? CVL’s new CEO is betting on it
- 5 numbers making dentists optimistic
- 25 state behavioral health policy updates
- Wisconsin woman accused of posing as fake dentist ordered to pay customer $144K
- Dentists battle insurance woes: 5 updates
- Philadelphia dentist dies at 86
- 4 injured after car crashes into North Carolina pediatric dental office
- Mental healthcare provider gaps, by state
- Park Dental Partners posts $66.2M in Q2 revenue
- 28 new behavioral health study findings to know
- 23 new behavioral health projects to know
- Aspen Dental continues 2026 growth with new Chicago practice
- Major PBMs agree to offer TrumpRx pricing information to members
- Providence reports $400M operating improvement halfway through 2026
- A look at where Aetna is seeing value-based care success in Medicare Advantage
- Nationwide program to quit smoking would save US $12B: Study
- Rare Bacteria In Coastal Waters Has Killed 7 This Summer
- Angelalign to appeal court’s decision in clear aligner patent infringement case
- It's crunch time for Karyopharm as company faces potential default next month
- UNC Health Pardee completes 23-bed behavioral health center
- Oregon State Hospital superintendent out after less than a month
- Affordable Care completes recapitalization, enters ‘next chapter’ of growth
- March of Dimes: Maternity care deserts persist, Medicaid cuts threaten to curb access further
- Trump administration refers providers, PBMs to DOJ over youth gender care billing
- Socializing: A Prescription For Healthier Brain Aging
- Taking The Stairs May Lower Your Risk Of Dying From Heart Disease
- Obesity not a 'zero-sum game' as patients crave optionality, Novo CEO says: Reuters
- AZ's blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER says
- How consumerization is reshaping pharma marketing
- Sweet Tooth? It Could Be Shaping Your Decisions, Study Says
- Stressed Parents Turn To Screens For Help, Study Finds
- Gambling Linked To Mental Health Problems Among College Students
- Hospitals Say They Found A Tool To Help Reduce Childbirth Risks: Wristbands
- Listen to the Latest ‘KFF Health News Minute’
- Readers Speak Out on Work Requirements, Federal Data Grab, Opioid Payback Cash
- People With Disabilities Say Medicaid’s Limits on Income Stifle Career Advancement
- Abbott to pump up blood supply with $1M college sports prize amid US crisis
- Neurocrine stands by blockbuster hopeful Vykat XR as Prader-Willi docs raise potential safety flags
- Appeals court tosses methodology for calculating NSA qualifying payment amounts
- UC San Diego Health, West Health launch $40M accelerator for 'tech-forward' coordinated care
- Epic releases Care Everywhere diagnostic image exchange to tackle healthcare's 'CD problem'
- FDA Wants More Information From Food Makers On New Food Chemicals
- Cityblock unveils partnership with Humana in North Carolina
- Antelope Recovery, offering SUD care for teens, to expand Spanish services in Colorado
- Legend interim CEO talks rising competition as Carvykti maker posts first profit
- Aspirin/Omega-3 Combo Matches Antibiotics In Treating Gum Disease, Trial Finds
- Endometriosis Linked To Higher Type 2 Diabetes Risk
- Cedar launches Kora Platform to build out agentic AI for medical billing
- Sharp HealthCare announces another reorganization affecting 260 workers
- Alfasigma gains arthritis drug, access to new markets with M&A play
- Common Health Coalition secures $100M from OpenAI Foundation to boost hepatitis C cure rates
- Lilly takes 6 companies to court for selling retatrutide knockoffs
- Tamiflu Helps Keep Severely Ill Kids Out Of The ICU, Study Finds
- 'Normal' Can Backfire During Doctor/Patient Discussions
- Experimental Pulse Oximeter Accurate Regardless Of Skin Tone, Researchers Say
- Suvi Health launches ambient AI solution for patients to reduce hospital stays and support care transitions
- The biggest payer and provider trends from Q2
- Patients Wary Of Governments, Companies Pushing AI As A Rural Healthcare Solution
- Years After He Quit Smoking, a Lung Cancer Scan Saved His Life
- Hospital Prepayment Requirements Add New Wrinkles to Patients’ Financial Responsibility
- Hospitals Say They Found a Tool To Help Reduce Childbirth Risks: Wristbands
- Fresenius pulls one batch of Actemra biosim over glass particle concerns
- Oracle Health debuts revamped patient portal with an AI upgrade
- Snapchat creates ad format to support pharma disclosure needs
- CMS ends Medicaid, CHIP funding for gender-affirming care for minors
- Healthcare CFOs face growing decision-making expectations. Many say they aren't ready
- Assort Health rolls out AI agent to automate referrals for specialty practices and health systems
- Claims data transparency empowers employers to act on affordability: survey
- Hims & Hers posts $753M in Q2 revenue as it preps for push into peptide market
- Executive Order Calls For Fewer Routine Childhood Vaccines, Doctors Push Back
- Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas
- Real-World Performance Of Alzheimer's Drug, Leqembi, Matches Trial Data, Study Finds
- Study Finds Undisclosed Chemicals In Most Personal Care Products
- Senators introduce bipartisan legislation to further antimicrobial resistance research
- CMS' mandatory VBC programs brought substantial administrative costs for hospitals: study
- Attruby cruises toward blockbuster land as BridgeBio CEO spots ‘stabilizer-first’ ATTR market
- WuXi AppTec scores temporary win amid fight over DOD's Chinese military company brand
- Barbie And Ken Fade From Fantasy, Offer More Realistic Proportions, Study Finds
- Children Should Get Flu Vaccine, Top Pediatrics Group Recommends
- Together, Two Everyday Health Factors Double Death Risk In Midlife And Beyond
- Many States Cover Doula Care, But Access To A 'Birthing Bestie' Is Often Out Of Reach
- Patients Wary of Governments, Companies Pushing AI as a Rural Healthcare Solution
- A Federal Policy Is Complicating How Organizations Battle the Opioid Crisis
- Chairman Paul S. Atkins Letter to Robert Walley, Chair, CAT NMS Plan Operating Committee
- Trump signs executive order to overhaul pediatric vaccine recommendations
- Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path
- Jalapeño Recall Reaches Seven Grocery Chains In 26 States
- New Melanoma Drug, Tudriqev, Based On Herpes Virus Granted FDA Accelerated Approval
- Even Light Exercise May Lower Stroke Risk For People With A-fib
- Working At Home Makes Breastfeeding Harder, Not Easier, Study Says
- Kidney Dialysis: Here's What You Need To Know
- What 524B and QMSR Change About Medical Device Risk
- Taking Lean Manufacturing to the Next Level
- Why Few MedTech Sales Teams Are Using AI Where It Matters Most
- Abbott casts telenovela star Gabriela Spanic to take the drama out of colon cancer screening
- Zepbound Lowers Heart Attack, Stroke Risk Among Type 2 Diabetics
- Heart Problems Linked To Brain Shrinkage Among People With Genetic Risk For Alzheimer's
- Budget Battle Erupts In Nation's Capital Over Opioid Settlement Money
- Rising Global Heat Linked To Mental Health Risks In Children
- Why Organizations Miss Emerging Product Risk: Understanding the engineering mechanisms that remain hidden long before complaint trends become visible
- Update on the SEC’s Work Toward Treasury Clearing Implementation [August 2026]
- FDA Reverses Course, Approves First mRNA Flu Shot
- Therapy Dogs Aid Stroke Rehab
- Can Yoga Calm A Grumpy Gut?
- Leo Pharma readies rare disease education push for 2nd annual GPP awareness day
- The Interface is the Risk: A MedTech Blueprint for AI and System Integration
- Restoring Regulatory Clarity: Statement on Technical Amendments to Rule 0‑1(a)(7)
- Beyond the Status Report: Using LLMs to Reveal the True State of SaMD Development
- Headstands and Summervaults: A Statement on Crypto Vaults and Lending Strategies
- Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Seeking Public Comment on Seeking Public Capital: Remarks Before the Small Business Capital Formation Advisory Committee
Michigan healthcare freedom community forum
Think the author of this post has the entities suing the Federal government wrong. It is the Dayton Chamber of Commerce suing, with the backing of the U.S. Chamber of Commerce:
US Chamber of Commerce sues over government's drug pricing power
By Jonathan Stempel - June 9, 2023June 9 (Reuters) - The U.S. Chamber of Commerce on Friday sued the federal government, challenging a new law that for the first time gives Medicare the power to negotiate drug prices with pharmaceutical companies.
In a complaint filed in federal court in Dayton, Ohio, the chamber said the pricing program violated drugmakers' due process rights under the U.S. Constitution by giving the government "unfettered discretion" to dictate maximum prices.
It also said the program would impose exorbitant penalties on drugmakers that don't accept those prices, and amounted to an ultimatum: "agree to whatever price the government names, or we'll smash up your business."
The U.S. Department of Health and Human Services administers Medicare through its Centers for Medicare & Medicaid Services.
A spokeswoman said the agency will vigorously defend the program, which is already helping lower healthcare costs for older adults and people with disabilities. "The law is on our side," she added.
Friday's lawsuit by the chamber, one of the most powerful U.S. business groups, came three days after Merck & Co (MRK.N) filed a similar lawsuit in Washington, D.C.
Both lawsuits contended that price controls would force drugmakers to pull back on developing new drugs, causing long-term harm to Americans and their health.
Other drugmakers have also objected to the pricing program, which is part of last year's Inflation Reduction Act. Pricing changes following negotiations on 10 costly drugs selected by CMS would take effect in 2026.
Americans pay more for prescription drugs than prices in any other country.
The Biden administration hopes to save $25 billion annually by 2031 by having Medicare, the government health plan for people 65 and over, negotiate prices.
White House spokeswoman Karine Jean-Pierre said on Tuesday the government was confident it would win the Merck case.
"There is nothing in the Constitution that prevents Medicare from negotiating lower drug prices," she said.
The chamber also warned that allowing the pricing program would set a bad precedent.
"After all, if the government can impose price controls in the pharmaceutical industry, why not elsewhere?" Chief Policy Officer Neil Bradley said in a statement.
The case is Dayton Area Chamber of Commerce et al v Becerra et al, U.S. District Court, Southern District of Ohio, No. 23-00156.
Now up to 4 Pharma/Chamber of Commerse lawsuits contesting Medicare drug price negotiation.
Pharmaceutical trade group sues US over Medicare drug price negotiation plans
NEW YORK, June 21 (Reuters) - The Pharmaceutical Research and Manufacturers of America (PhRMA), the leading industry lobby group, and two other organizations on Wednesday said they were suing the U.S. government to block enforcement of a program that gives Medicare the power to negotiate drug prices.
In a complaint filed in a federal court in Texas, PhRMA along with the National Infusion Center Association and the Global Colon Cancer Association, which counts PhRMA and some drug companies as members, said the drug price negotiation program was unconstitutional.
This marks the fourth lawsuit challenging the law, which is part of President Joe Biden’s signature Inflation Reduction Act (IRA), after separate legal challenges by Merck & Co (MRK.N), Bristol Myers Squibb (BMY.N), and the influential business group the U.S. Chamber of Commerce.
The pharmaceutical industry claims negotiating prices of its products with the government health plan for Americans age 65 and older will curtail profits and compel them to pull back on developing groundbreaking new treatments.
PhRMA represents many of the largest pharmaceutical companies in the world, including Merck and Bristol Myers.
Americans pay more for prescription medicines than any other country. The Biden administration's drug pricing reform aims to save $25 billion annually by 2031 through price negotiations for the drugs most costly to Medicare.
The latest lawsuit argues that the "unrestrained authority" given to the Department for Health and Human Services (HHS) by Congress conflicts with the United States' separation-of-power principle.
"Congress took a series of unconstitutional shortcuts, giving the executive branch the open ended task of replacing market based prices in Medicare with an entirely new set of prices at the (Medicare) agency's own choosing," PhRMA general counsel James Stansel said at a press conference.
The lawsuit also contends that the price negotiation program violates the U.S. Constitution's Eight Amendment, which protects against excessive fines, and Fifth Amendment by exempting key decisions from public input.
PhRMA and the other two groups are seeking an injunction against the price caps and a declaration that the IRA's price negotiation is unconstitutional.
The negotiations are scheduled to start in September after the agency that runs Medicare and Medicaid releases its list of 10 costly drugs initially selected for the process, with the agreed prices taking effect in 2026.
The suits challenging the plan have been filed in four different federal courts, with Merck's in Washington, D.C., the Chamber of Commerce in Ohio and Bristol Myers' in New Jersey.
In response to the previous lawsuits, the White House said there is nothing in the U.S. Constitution that prevents Medicare from negotiating lower drug prices.
A spokesperson for HHS on Wednesday said the law is on its side.
“As the (HHS) secretary has already made clear, we will vigorously defend the president’s drug price negotiation law, which is already helping to lower healthcare costs for seniors and people with disabilities."
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.























